LEGN · Legend Biotech Corp · Documents
Market Cap
$3.62B
Shares
194.49M
Volume · Oct 22
451.96K
Avg daily vol (3M)
2.3M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| 6-K | Legend Biotech announced the U.S. Food and Drug Administration cleared LB2501’s IND application on October 15, 2026, making it the first known dual-targeting in vivo CAR-T therapy to receive FDA IND clearance and supporting a planned U.S. Phase 1/2 study. | 2026-10-15 | — | |
| 6-K | Legend Biotech announced that CARVYKTI generated approximately $710 million in net trade sales during the quarter ended September 30, 2026; the figure was provided by Janssen and has not been independently verified. | 2026-10-13 | — | |
| 6-K | — | 2026-09-25 | 2026-09-24 | |
| 6-K | — | 2026-09-24 | — | |
| 6-K | — | 2026-09-15 | — | |
| 6-K | — | 2026-09-14 | — | |
| 6-K | — | 2026-08-18 | — | |
| 6-K | — | 2026-08-11 | 2026-06-30 | |
| 6-K | — | 2026-08-06 | — | |
| 6-K | — | 2026-07-27 | — | |
| 6-K | — | 2026-07-15 | — | |
| 6-K | — | 2026-06-22 | — | |
| 6-K | — | 2026-06-15 | — | |
| 6-K | — | 2026-06-02 | — | |
| 6-K | — | 2026-06-01 | — | |
| 6-K | — | 2026-05-21 | — | |
| 6-K | — | 2026-05-12 | 2026-03-31 | |
| 6-K | — | 2026-04-14 | — | |
| 6-K | — | 2026-03-10 | — | |
| 20-F | — | 2026-03-10 | 2025-12-31 | |
| 6-K | — | 2026-02-06 | — | |
| 6-K | — | 2026-01-23 | — | |
| 6-K | — | 2026-01-21 | — | |
| 6-K | — | 2026-01-14 | — | |
| 6-K | — | 2026-01-12 | — | |
| 6-K | — | 2025-12-08 | — | |
| 6-K | — | 2025-11-12 | 2025-09-30 | |
| 6-K | — | 2025-11-03 | — | |
| 6-K | — | 2025-10-14 | — | |
| 6-K | — | 2025-10-14 | 2025-10-10 | |
| 6-K | — | 2025-10-07 | — | |
| 6-K | — | 2025-08-18 | — | |
| 6-K | — | 2025-08-11 | 2025-06-30 | |
| 6-K | — | 2025-07-16 | — | |
| 6-K | — | 2025-06-30 | — | |
| 6-K | — | 2025-06-12 | — | |
| 6-K | — | 2025-06-06 | — | |
| 6-K | — | 2025-06-05 | — | |
| 6-K | — | 2025-06-03 | — | |
| 6-K | — | 2025-05-23 | 2025-05-22 | |
| 6-K | — | 2025-05-14 | — | |
| 6-K | — | 2025-05-13 | 2025-03-31 | |
| 6-K | — | 2025-05-12 | — | |
| 6-K | — | 2025-04-15 | — | |
| 20-F | — | 2025-03-11 | 2024-12-31 | |
| 6-K | — | 2025-03-11 | — | |
| 6-K | — | 2025-01-22 | — | |
| 6-K | — | 2025-01-14 | — | |
| 6-K | — | 2024-12-23 | — | |
| 6-K | — | 2024-12-10 | 2024-12-09 |
Showing 1–50 of 207 filings
Key facts
CIK
1801198
CUSIP
52490G102
13F (30d)
14 filings
14 filers
Visit website
Investor relations